All In Biotech

Drug Trial Radar · NCT05746611

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

To Conduct a Phase IV Clinical Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein in Community Population Aged 6 Months and Above.

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 7,500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,500

Actual

Start

Apr 17, 2023

Primary completion

May 13, 2024

Study completion May 13, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients. Cohort I was injected with EC and TB-PPD in both arms, and cohort II was injected with EC only

Conditions

  • Latent Tuberculosis Infection

Interventions

  • Recombinant Mycobacterium tuberculosis fusion protein for injectionBiological

    For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method

  • TB-PPD was injectedBiological

    For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 0 minute after injection.
  2. In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 24 hours after injection.
  3. In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 48 hours after injection.
  4. In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 72 hours after injection.
  5. In Cohort 2, the diameter of redness or induration at the reaction siteTime frame: 0 minute after the skin test
  6. In Cohort 2, the diameter of redness or induration at the reaction siteTime frame: Within 48 to 72 hours after skin testing
  7. Number of cases in which all adverse events occurred.Time frame: The skin test was performed 72 hours after injection.
  8. Incidence of SAETime frame: Incidence of SAE within 72 hours after full vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

    Liuzhou, Guangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.